Search research articles
Contact Us
Filters
Showing results (101-110 of 185) with videos related to
Page
of 19
Sort By:
Cancer Biotherapy & Radiopharmaceuticals
|
January 13, 2022
A Pilot Study of Hepatic Irradiation with Yttrium-90 Microspheres Followed by Immunotherapy with Ipilimumab and Nivolumab for Metastatic Uveal Melanoma
David R Minor, Kevin B Kim, Ricky T Tong, et al.
Journal for Immunotherapy of Cancer
|
February 20, 2025
Phase I dose-escalation and pharmacodynamic study of STING agonist E7766 in advanced solid tumors
Jason J Luke, David J Pinato, Dejan Juric, et al.
Nature Communications
|
September 4, 2019
Tumor-reprogrammed resident T cells resist radiation to control tumors
Ainhoa Arina, Michael Beckett, Christian Fernandez, et al.
Cancer Chemotherapy and Pharmacology
|
February 13, 2015
Alliance A091103 a phase II study of the angiopoietin 1 and 2 peptibody trebananib for the treatment of angiosarcoma
Sandra P D' Angelo, Michelle R Mahoney, Brian A Van Tine, et al.
The Journal of Clinical Investigation
|
May 15, 2023
Partial tumor irradiation plus pembrolizumab in treating large advanced solid tumor metastases
Mark C Korpics, Benjamin E Onderdonk, Rebekah E Dadey, et al.
Melanoma Research
|
September 14, 2018
Results from phase II trial of HSP90 inhibitor, STA-9090 (ganetespib), in metastatic uveal melanoma
Shalin Shah, Jason J Luke, Heather A Jacene, et al.
Oncology
|
June 24, 2019
A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors
David Hong, Drew Rasco, Michael Veeder, et al.
Cancers
|
April 27, 2024
Th2 Cells Are Associated with Tumor Recurrence Following Radiation
Mohamed K Abdelhakiem, Riyue Bao, Phillip M Pifer, et al.
Cancer Immunology Research
|
April 12, 2017
Clinical Features of Acquired Resistance to Anti-PD-1 Therapy in Advanced Melanoma
Daniel Y Wang, Zeynep Eroglu, Alpaslan Ozgun, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 29, 2018
Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037)
Tara C Mitchell, Omid Hamid, David C Smith, et al.
Page
of 19
Search research articles
Search
Showing results (101-110 of 185) with videos related to
Sort By:
Page
of 19
Cancer Biotherapy & Radiopharmaceuticals
|
January 13, 2022
A Pilot Study of Hepatic Irradiation with Yttrium-90 Microspheres Followed by Immunotherapy with Ipilimumab and Nivolumab for Metastatic Uveal Melanoma
David R Minor, Kevin B Kim, Ricky T Tong, et al.
Journal for Immunotherapy of Cancer
|
February 20, 2025
Phase I dose-escalation and pharmacodynamic study of STING agonist E7766 in advanced solid tumors
Jason J Luke, David J Pinato, Dejan Juric, et al.
Nature Communications
|
September 4, 2019
Tumor-reprogrammed resident T cells resist radiation to control tumors
Ainhoa Arina, Michael Beckett, Christian Fernandez, et al.
Cancer Chemotherapy and Pharmacology
|
February 13, 2015
Alliance A091103 a phase II study of the angiopoietin 1 and 2 peptibody trebananib for the treatment of angiosarcoma
Sandra P D' Angelo, Michelle R Mahoney, Brian A Van Tine, et al.
The Journal of Clinical Investigation
|
May 15, 2023
Partial tumor irradiation plus pembrolizumab in treating large advanced solid tumor metastases
Mark C Korpics, Benjamin E Onderdonk, Rebekah E Dadey, et al.
Melanoma Research
|
September 14, 2018
Results from phase II trial of HSP90 inhibitor, STA-9090 (ganetespib), in metastatic uveal melanoma
Shalin Shah, Jason J Luke, Heather A Jacene, et al.
Oncology
|
June 24, 2019
A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors
David Hong, Drew Rasco, Michael Veeder, et al.
Cancers
|
April 27, 2024
Th2 Cells Are Associated with Tumor Recurrence Following Radiation
Mohamed K Abdelhakiem, Riyue Bao, Phillip M Pifer, et al.
Cancer Immunology Research
|
April 12, 2017
Clinical Features of Acquired Resistance to Anti-PD-1 Therapy in Advanced Melanoma
Daniel Y Wang, Zeynep Eroglu, Alpaslan Ozgun, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 29, 2018
Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037)
Tara C Mitchell, Omid Hamid, David C Smith, et al.
Page
of 19